Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG (antibody)-based targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR and cMET.

To read more please visit:

Fusion Pharmaceuticals Announces Presentation Of Preclinical Data Supporting FPI-2068, A Novel Targeted Alpha Therapy For EGFR-CMET Expressing Cancers

Source: Fusion